R&D channel feed – Endpoints News

R&D channel feed

Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug

3 years ago

Lenz Therapeutics eyes better vision than AbbVie, Orasis with $80M+ for three PhIII trials

3 years ago

Immuneering cuts neuroscience programs to focus on oncology, extend cash runway

3 years ago

Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases

3 years ago

Noema Pharma raises $112M Series B to advance CNS disorder pipeline with Roche candidates

3 years ago

Merck unwraps full PhIII data on the centerpiece from its $11.5B Acceleron buyout: #ACC23

3 years ago

Large biopharma companies cull about 40 immuno-oncology programs over the last two quarters

3 years ago

AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps

3 years ago

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

3 years ago

With PhII success, BridgeBio wades deeper into dwarfism drug debate

3 years ago

Aclaris shares halved after mid-stage skin disorder fail

3 years ago

Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure

3 years ago

Cytokinetics' heart drug shows positive results after FDA rejection of earlier treatment: #ACC23

3 years ago

Esperion unveils long-awaited data on cholesterol pill's ability to cut cardiovascular risk: #ACC23

3 years ago

Praxis stock tanks after mid-stage movement disorder trial miss

3 years ago

Roche, Exelixis' Tecentriq/Cabometyx combo flunks second PhIII

3 years ago

Intellia gets FDA clearance to start hereditary angioedema gene editing trial in US

3 years ago

MorphoSys chops back again, this time cutting preclinical efforts in late-stage push

3 years ago

Scoop: Ascletis' NASH subsidiary scraps US PhII trial in favor of China

3 years ago

Novo Nordisk touts expansion in Boston, cuts about 100 jobs in two other US cities

3 years ago

A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it

3 years ago

Keytruda hits one primary endpoint for use before and after surgery in lung cancer

3 years ago

G1 Therapeutics delays PhIII readout of lead drug — will cut 30% of staff, CFO to exit

3 years ago

Ready to turn a new page, Landos Biopharma offloads former lead program to founder

3 years ago

First page Previous page 94 95 969798 99 100 Next page Last page